Combination therapy associating a TGF-beta antagonist with a chemotherapeutic agent

(19)

(11)

EP 2 248 895 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	21.09.2016 Bulletin 2016/38

(45)	Mention of the grant of the patent:
	06.07.2016 Bulletin 2016/27

(21)	Application number: 10009016.6

(22)	Date of filing: 20.12.2004

(51)

International Patent Classification (IPC):

C12N 15/113^(2010.01)
A61K 31/04^(2006.01)
A61K 31/52^(2006.01)
A61K 38/18^(2006.01)
C07K 14/495^(2006.01)

A61K 31/7125^(2006.01)
A61K 31/166^(2006.01)
A61K 31/7048^(2006.01)
A61P 35/00^(2006.01)

(54)	Combination therapy associating a TGF-beta antagonist with a chemotherapeutic agent Kombinations-therapie die ein TGF-beta Antagonisten mit einem Chemotherapeutikum assoziiert Thérapie combinatoire associant un antagoniste du TGF-beta avec un agent chimiothérapeutique

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

(30)

Priority:

19.12.2003 EP 03029367
05.02.2004 US 541771 P

(43)	Date of publication of application:
	10.11.2010 Bulletin 2010/45

(60)	Divisional application:
	16177969.9

(62)	Application number of the earlier application in accordance with Art. 76 EPC:
	04804940.7 / 1694840

(73)	Proprietor: Autotelic LLC
	City of Industry, CA 91748 (US)

(72)	Inventors:
	Schlingensiepen, Karl-Hermann 93093 Donaustauf (DE) Schlingensiepen, Reimar 93051 Regensburg (DE)

(74)	Representative: V.O.
	P.O. Box 87930 2508 DH Den Haag 2508 DH Den Haag (NL)

(56)

References cited: :

WO-A-94/25588
WO-A-2004/005552

WO-A-99/63975

ARTEAGA C L ET AL: "REVERSAL OF TAMOXIFEN RESISTANCE OF HUMAN BREAST CARCINOMAS IN VIVO BY NEUTRALIZING ANTIBODIES TO TRANSFORMING GROWTH FACTOR-BETA", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 91, no. 1, 6 January 1999 (1999-01-06), pages 46-53, XP000940473, ISSN: 0027-8874
WOJTOWICZ-PRAGA SLAWOMIR: "Reversal of tumor-induced immunosuppression by TGF-beta inhibitors.", INVESTIGATIONAL NEW DRUGS, vol. 21, no. 1, February 2003 (2003-02), pages 21-32, XP008035079, ISSN: 0167-6997
JACHIMCZAK P ET AL: "THE EFFECT OF TRANSFORMING GROWTH FACTOR-BETA 2-SPECIFIC PHOSPHOROTIHIOATE-ANTI-SENSE OLIGODEOXYNUCLEOTIDES IN REVERSING CELLULAR IMMUNOSUPPRESSION IN MALIGNANT GLIOMA", JOURNAL OF NEUROSURGERY, vol. 78, no. 6, 1993, pages 944-951, XP000886109, ISSN: 0022-3085
YU D ET AL: "HYBRID OLIGONUCLEOTIDES: SYNTHESIS, BIOPHYSICAL PROPERTIES STABILITY STUDIES, AND BIOLOGICAL ACTIVITY", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 4, no. 10, 1996, pages 1685-1692, XP000644792, ISSN: 0968-0896

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).